Wang M, Liang H, Wang W, et al. - In first‐line treatment of patients suffering from advanced non–small cell lung cancer (NSCLC), researchers investigated the rate of immune‐related adverse events (irAEs) with a PD‐(L)1 (programmed death ligand 1) inhibitor plus chemotherapy (I+C) vs a PD‐(L)1 inhibitor alone (I) via this meta‐analysis. They also assessed the indirect relative risk (RR) of I+C vs I. They computed pooled rates of irAEs at different grades via a single‐arm meta‐analysis weighted by sample size, and ascertained RRs via direct meta‐analysis and indirect treatment comparison. They found that a PD‐(L)1 inhibitor plus chemotherapy resulted in reduced rates of most irAEs (ie, pneumonitis and endocrine and skin reactions) as well as the overall rate when compared with a PD‐(L)1 inhibitor alone as a first‐line treatment of NSCLC.